The Experts below are selected from a list of 726 Experts worldwide ranked by ideXlab platform
Barbara Gales - One of the best experts on this subject based on the ideXlab platform.
-
development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy
Kidney International, 1994Co-Authors: Jorge A Ramirez, Barbara Gales, William G Goodman, Thomas R Belin, Yun ChonAbstract:Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Intermittent calcitriol therapy is commonly used to treat secondary hyperparathyroidism in patients undergoing regular dialysis, but there is little available information about the histologic response of bone to this form of therapy. Accordingly, 14 children and adolescents with biopsy-proven secondary hyperparathyroidism were treated with intermittent oral or intraperitoneal doses of calcitriol for 12 months. Biochemical indices of mineral metabolism including serum intact PTH levels were measured monthly throughout the study, and bone biopsies were repeated at the end of treatment. Before treatment, 11 patients had Osteitis fibrosa and three had mild lesions of secondary hyperparathyroidism. Histologic improvement was seen in 12 of 14 patients, and Osteitis fibrosa resolved in 10 of 11 cases. Bone formation decreased in all patients during intermittent calcitriol therapy, falling from 861 ± 380 to 150 ± 170 µm 2 /mm 2 /day, P
-
biochemical markers of renal osteodystrophy in pediatric patients undergoing capd ccpd
Kidney International, 1994Co-Authors: William Oppenheim, Jorge A Ramirez, Gino V Segre, Barbara Gales, Isidro B. SaluskyAbstract:Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Serum intact PTH [1–84] levels were evaluated as a potential non-invasive method for the diagnosis of renal osteodystrophy in children treated with CAPD/CCPD. Sixty-eight bone biopsy samples were obtained from 55 patients, aged 13 ± 5 (X ± SD) years, undergoing CAPD/CCPD for 29 ± 13 months; Osteitis fibrosa was present in 34 cases, mild lesions of secondary hyperparathyroidism in six, 15 had adynamic lesions, and 13 were classified as normal histology. Serum calcium levels were higher in patients with adynamic bone or normal bone histology than in those with secondary hyperparathyroidism, whereas serum phosphorus, alkaline phosphatase and PTH levels were greater in patients with Osteitis fibrosa. The combination of a serum PTH level >200 pg/ml and a serum calcium value 10 mg/dl. Higher serum calcium levels and serum PTH values within or below the normal range characterize patients with the adynamic lesion of renal osteodystrophy. Serum PTH levels of approximately 200 pg/ml are useful for distinguishing patients with low-turnover lesions of renal osteodystrophy from those with secondary hyperparathyroidism.
Gino V Segre - One of the best experts on this subject based on the ideXlab platform.
-
risk factors for renal osteodystrophy a multivariant analysis
Journal of Bone and Mineral Research, 2009Co-Authors: Gavril Hercz, Gino V Segre, Celia M T Greenwood, Arif Manuel, Carl Saiphoo, Stanley S A Fenton, Donald J SherrardAbstract:To assess the risk factors associated with renal osteodystrophy, we examined the database of 256 patients who were prospectively studied in three Toronto dialysis centers between October of 1987 and 1989. The potential risk factors examined included age, sex, type and duration of dialysis, type and dose of phosphate binders, vitamin D treatment, and history of diabetes mellitus, renal allograft failure, parathyroidectomy, and bilateral nephrectomy. All patients had undergone a bone biopsy and were categorized into one of four disease groupings: (1) Osteitis fibrosa and mixed bone disease, (2) aluminum bone disease, (3) mild bone disorder, and (4) aplastic bone disorder. The mean (±SD) age of the patients at bone biopsy was 57 ± 15 years, and 62% were men. Forty-five percent of patients were treated by hemodialysis and 55% by peritoneal dialysis. The mean duration of dialysis was 4 ± 4 years. Twenty-five percent were also diabetic. The most common disorder was the aplastic (or “adynamic”) bone disorder, found in 34% of patients. Aluminum bone disease was found in 27%, Osteitis fibrosa or mixed bone disease in 27%, and mild bone disorder in 12% of patients. Cumulative intake of aluminum gels was associated with aluminum bone disease, whereas peritoneal dialysis with supraphysiologic calcium concentrations, ingestion of calcium carbonate, and diabetes mellitus were associated with both mild bone disorder and aplastic bone disorder. These three latter risk factors may be important in predisposing patients to a low bone turnover state through modulation of parathyroid hormone secretion. Thus, recent increases in the frequencies of these risk factors in dialysis patients are associated with a high prevalence of aplastic bone disorder. The clinical significance of this bone disorder remains to be defined.
-
biochemical markers of renal osteodystrophy in pediatric patients undergoing capd ccpd
Kidney International, 1994Co-Authors: William Oppenheim, Jorge A Ramirez, Gino V Segre, Barbara Gales, Isidro B. SaluskyAbstract:Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Serum intact PTH [1–84] levels were evaluated as a potential non-invasive method for the diagnosis of renal osteodystrophy in children treated with CAPD/CCPD. Sixty-eight bone biopsy samples were obtained from 55 patients, aged 13 ± 5 (X ± SD) years, undergoing CAPD/CCPD for 29 ± 13 months; Osteitis fibrosa was present in 34 cases, mild lesions of secondary hyperparathyroidism in six, 15 had adynamic lesions, and 13 were classified as normal histology. Serum calcium levels were higher in patients with adynamic bone or normal bone histology than in those with secondary hyperparathyroidism, whereas serum phosphorus, alkaline phosphatase and PTH levels were greater in patients with Osteitis fibrosa. The combination of a serum PTH level >200 pg/ml and a serum calcium value 10 mg/dl. Higher serum calcium levels and serum PTH values within or below the normal range characterize patients with the adynamic lesion of renal osteodystrophy. Serum PTH levels of approximately 200 pg/ml are useful for distinguishing patients with low-turnover lesions of renal osteodystrophy from those with secondary hyperparathyroidism.
Jorge A Ramirez - One of the best experts on this subject based on the ideXlab platform.
-
development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy
Kidney International, 1994Co-Authors: Jorge A Ramirez, Barbara Gales, William G Goodman, Thomas R Belin, Yun ChonAbstract:Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Intermittent calcitriol therapy is commonly used to treat secondary hyperparathyroidism in patients undergoing regular dialysis, but there is little available information about the histologic response of bone to this form of therapy. Accordingly, 14 children and adolescents with biopsy-proven secondary hyperparathyroidism were treated with intermittent oral or intraperitoneal doses of calcitriol for 12 months. Biochemical indices of mineral metabolism including serum intact PTH levels were measured monthly throughout the study, and bone biopsies were repeated at the end of treatment. Before treatment, 11 patients had Osteitis fibrosa and three had mild lesions of secondary hyperparathyroidism. Histologic improvement was seen in 12 of 14 patients, and Osteitis fibrosa resolved in 10 of 11 cases. Bone formation decreased in all patients during intermittent calcitriol therapy, falling from 861 ± 380 to 150 ± 170 µm 2 /mm 2 /day, P
-
biochemical markers of renal osteodystrophy in pediatric patients undergoing capd ccpd
Kidney International, 1994Co-Authors: William Oppenheim, Jorge A Ramirez, Gino V Segre, Barbara Gales, Isidro B. SaluskyAbstract:Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Serum intact PTH [1–84] levels were evaluated as a potential non-invasive method for the diagnosis of renal osteodystrophy in children treated with CAPD/CCPD. Sixty-eight bone biopsy samples were obtained from 55 patients, aged 13 ± 5 (X ± SD) years, undergoing CAPD/CCPD for 29 ± 13 months; Osteitis fibrosa was present in 34 cases, mild lesions of secondary hyperparathyroidism in six, 15 had adynamic lesions, and 13 were classified as normal histology. Serum calcium levels were higher in patients with adynamic bone or normal bone histology than in those with secondary hyperparathyroidism, whereas serum phosphorus, alkaline phosphatase and PTH levels were greater in patients with Osteitis fibrosa. The combination of a serum PTH level >200 pg/ml and a serum calcium value 10 mg/dl. Higher serum calcium levels and serum PTH values within or below the normal range characterize patients with the adynamic lesion of renal osteodystrophy. Serum PTH levels of approximately 200 pg/ml are useful for distinguishing patients with low-turnover lesions of renal osteodystrophy from those with secondary hyperparathyroidism.
Isidro B. Salusky - One of the best experts on this subject based on the ideXlab platform.
-
biochemical markers of renal osteodystrophy in pediatric patients undergoing capd ccpd
Kidney International, 1994Co-Authors: William Oppenheim, Jorge A Ramirez, Gino V Segre, Barbara Gales, Isidro B. SaluskyAbstract:Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Serum intact PTH [1–84] levels were evaluated as a potential non-invasive method for the diagnosis of renal osteodystrophy in children treated with CAPD/CCPD. Sixty-eight bone biopsy samples were obtained from 55 patients, aged 13 ± 5 (X ± SD) years, undergoing CAPD/CCPD for 29 ± 13 months; Osteitis fibrosa was present in 34 cases, mild lesions of secondary hyperparathyroidism in six, 15 had adynamic lesions, and 13 were classified as normal histology. Serum calcium levels were higher in patients with adynamic bone or normal bone histology than in those with secondary hyperparathyroidism, whereas serum phosphorus, alkaline phosphatase and PTH levels were greater in patients with Osteitis fibrosa. The combination of a serum PTH level >200 pg/ml and a serum calcium value 10 mg/dl. Higher serum calcium levels and serum PTH values within or below the normal range characterize patients with the adynamic lesion of renal osteodystrophy. Serum PTH levels of approximately 200 pg/ml are useful for distinguishing patients with low-turnover lesions of renal osteodystrophy from those with secondary hyperparathyroidism.
William Oppenheim - One of the best experts on this subject based on the ideXlab platform.
-
biochemical markers of renal osteodystrophy in pediatric patients undergoing capd ccpd
Kidney International, 1994Co-Authors: William Oppenheim, Jorge A Ramirez, Gino V Segre, Barbara Gales, Isidro B. SaluskyAbstract:Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Serum intact PTH [1–84] levels were evaluated as a potential non-invasive method for the diagnosis of renal osteodystrophy in children treated with CAPD/CCPD. Sixty-eight bone biopsy samples were obtained from 55 patients, aged 13 ± 5 (X ± SD) years, undergoing CAPD/CCPD for 29 ± 13 months; Osteitis fibrosa was present in 34 cases, mild lesions of secondary hyperparathyroidism in six, 15 had adynamic lesions, and 13 were classified as normal histology. Serum calcium levels were higher in patients with adynamic bone or normal bone histology than in those with secondary hyperparathyroidism, whereas serum phosphorus, alkaline phosphatase and PTH levels were greater in patients with Osteitis fibrosa. The combination of a serum PTH level >200 pg/ml and a serum calcium value 10 mg/dl. Higher serum calcium levels and serum PTH values within or below the normal range characterize patients with the adynamic lesion of renal osteodystrophy. Serum PTH levels of approximately 200 pg/ml are useful for distinguishing patients with low-turnover lesions of renal osteodystrophy from those with secondary hyperparathyroidism.
